Neuropathic ocular pain, a complex condition resulting from nerve damage in the eye, has seen a surge in collaborative efforts among key stakeholders in the field. Leading players in the market are uniting to develop innovative comprehensive management strategies. Simultaneously, there has been a notable increase in public awareness regarding the regarding the significance of maintaining optimal eye health. This heightened awareness has prompted individuals to seek timely medical intervention, enhancing the overall management of neuropathic ocular pain and its associated complications.
According to Coherent Market Insights, The market for Neuropathic Ocular Pain estimated at US$ 2,401.3 million in 2022 and is anticipated to grow at a CAGR of 5.8% from 2023 to 2030 to reach US$ 3,769.9 million.
Top Companies in the Neuropathic Ocular Pain Industry:
1. OKYO Pharma Limited:
Founded in 2007 and is headquartered in London, UK. The company specializes in developing innovative therapies for various ocular conditions, including neuropathic ocular pain. Operating in multiple countries, such as the US and Germany, OKYO Pharma focuses on precision medicine to target specific pathways involved in ocular pain transmission. Their recent market advancement includes successful preclinical trials of a novel pain-modulating compound for neuropathic ocular pain treatment.
2. Novartis AG:
Established in 1996, Novartis AG is based in Basel, Switzerland. With a global presence in around 155 countries, including the UK and Japan, Novartis is a pharmaceutical giant dedicated to advancing healthcare solutions. The company’s specialized ophthalmology division works on neuropathic ocular pain treatments, exemplified by their recent development of an innovative topical therapy utilizing nanotechnology to deliver targeted relief to affected nerve endings.
3. SALVAT:
Founded in 1955, SALVAT is headquartered in Barcelona, Spain. Operating in more than 80 countries, including Brazil and Italy, SAVALT specializes in developing and commercializing innovative ophthalmic solutions. Their recent market contribution involves the introduction of a novel eye drop formulation containing neuropathic ocular pain by preserving nerve health.
4. Kala Pharmaceuticals:
Established in 2009 and based in Watertown, USA. It mainly focuses on ophthalmic solutions. Operating primarily in the US, the company has introduced a revolutionary nanotechnology-based ocular insert for sustained relief in neuropathic ocular pain. This recent development has shown promising results in clinical trials, revolutionizing treatment approaches.
5. Spectra Vision Care:
Founded in 2002, Spectra Vision care is situated in Mumbai, India. Operating extensively across India and neighboring countries, the company specializes in eyecare products. Their recent contribution involves launching specialized contact lenses embedded with microtechnology, offering continuous therapeutic support for neuropathic ocular pain sufferers.
6. BRIM Biotechnology:
Established in 2010, BRIM is located in Seoul, South Korea. Operating primarily in Asia, including China and Japan, it focuses on innovative therapies for ocular conditions. Their recent market development encompasses a gene-editing approach to modulate pain-related genes, holding potential for transformative treatments for neuropathic ocular pain.
*Definition- The neuropathic ocular pain market refers to the commercial landscape involving products and treatments targeting pain resulting from nerve damage in the eye.
